-
Article
Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium
Quadruple therapy is effective for patients with heart failure with reduced ejection fraction, providing significant clinical benefits, including reduced mortality. Clinicians are now in an era focused on how ...
-
Article
Open AccessSodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review
Heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) are common and interrelated conditions, each with a significant burden of disease. HF and kidney disease progress through p...
-
Article
Investigating Potential Gender-Based Differential Item Functioning for Items in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Physical Limitations Domain
Women with heart failure report worse health-related quality of life on average, than men. This may result from actual differences in care or differing interpretations of and responses to survey questions. We ...
-
Article
Open AccessProtein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
There is increasing evidence that HFpEF is a heterogeneous clinical entity and distinct molecular pathways may contribute to pathophysiology. Leveraging unbiased proteomics to identify novel biomarkers, this s...
-
Article
The need for increased pragmatism in cardiovascular clinical trials
The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these ‘explanatory’ trial designs opti...
-
Article
Open AccessEffect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
To determine whether there were racial differences in short-term cardiometabolic responses to once-weekly exenatide (EQW) in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
-
Article
Open AccessPatients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study
Cardiovascular prognosis related to type 2 diabetes may not be adequately captured by information on comorbid conditions such as obesity and hypertension. To inform the cardiovascular prognosis among diabetic ...
-
Article
Open AccessGlycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study
Left ventricular structure and function abnormalities may be an early marker of cardiomyopathy among African Americans with diabetes (DM) even in the absence of coronary artery disease (CAD), arrhythmia, valvu...
-
Article
Open AccessThe SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also impro...
-
Article
Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure
We examined the relationship between pain severity and outcomes in patients with heart failure with reduced ejection fraction (HFrEF) in the HF-ACTION randomized controlled trial. Trends of health-related qual...
-
Article
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications
Multiple newer medications benefit patients with heart failure with reduced ejection fraction (HFrEF). While these therapies benefit the broad population with HFrEF, the efficacy and safety of these therapies ...
-
Article
Egg Consumption and Risk of Cardiovascular Disease: a Critical Review
Our aims are to explore the evidence for egg consumption effects on cardiovascular disease risk factors and the relationship between egg consumption with risk of coronary heart disease, stroke, heart failure, ...
-
Article
A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF)
Patients hospitalized for heart failure (HF) remain at high risk for early readmission. A post hoc analysis was performed of the biomarker substudy of the ASCEND-HF trial. An in-hospital congestion score was deri...
-
Article
Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does “X” Really Mark the Spot?
Explore controversial biomarker-guided management of patients with heart failure (HF) with reduced ejection fraction.
-
Article
Open AccessEffects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanism...
-
Article
Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials
Heart failure is a global pandemic and there has been a growing effort to enroll patients from different geographical regions in randomized controlled trials. In this review, we examined regional variation in ...
-
Article
Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction
We aimed to characterize the independent predictors of LVT following STEMI and the association with outcomes. The clinical predictors of left ventricular thrombus (LVT) formation after ST-segment elevation myo...
-
Article
Comorbidities in Heart Failure: Are There Gender Differences?
Compared to men, women with heart failure (HF) are often older, smoke less, and have more preserved ejection fraction (EF) and hypertensive HF rather than HF of ischemic etiology. Gender-stratified outcomes on...
-
Article
Pathophysiology and clinical evaluation of acute heart failure
Acute heart failure (AHF) is a complex syndrome characterized by the worsening of signs and symptoms of heart failure
- ...
-
Article
Site selection for heart failure clinical trials in the USA
There are more than 1 million primary hospitalizations for heart failure (HF) annually in the USA alone, and post-discharge outcomes remain persistently poor despite available therapies and quality improvement...
